France to tighten drug trial rules after fatal incident

The transcript discusses a delay in reporting an accident to the National Agency for Medicine Safety by laboratories, which only formally declared it four days after the first volunteer's hospitalization. Volunteers were not informed, affecting their consent to continue the trial. Biotrial must submit an action plan within a month or face suspension. Compliance with current regulations is questioned, and additional information from the laboratory may be necessary for authorization requests.

Quelles conséquences pourrait avoir le non-respect du plan d'action par Biotrial?

Quelles informations complémentaires auraient dû être fournies par le laboratoire selon le directeur général de la Santé?